Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of
Operable Stage III NSCLC.
10.3779/j.issn.1009-3419.2023.102.23
- Author:
Yun ZHANG
1
;
Shuang ZHOU
1
;
Wentao TAO
1
;
Rong LI
1
Author Information
1. Shanghai Chest Hospital, Clinical Research Center, Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200030, China.
- Publication Type:Journal Article
- Keywords:
Adverse events;
Lung neoplasms;
Neoadjuvant therapy;
Supervision
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung;
China;
Cisplatin;
Docetaxel;
Lung Neoplasms;
Neoadjuvant Therapy;
Programmed Cell Death 1 Receptor;
Quality of Life;
Reproducibility of Results;
Prospective Studies
- From:
Chinese Journal of Lung Cancer
2023;26(6):461-466
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Programmed cell death protein 1 (PD-1) combined with platinum containing dual drug chemotherapy is a new adjuvant treatment option for operable stage III non-small cell lung cancer (NSCLC), and the quality assurance of clinical trials of related drugs plays a crucial role in the results of the clinical trials. This study aims to explore the impact of adverse events (AEs) supervision on reducing treatment-related AEs in patients.
METHODS:66 NSCLC patients admitted to Shanghai Chest Hospital from July 2020 to October 2021 were prospectively collected. All the patients received 3 cycles of neoadjuvant treatment of Camrelizumab in combination with Docetaxel and Cisplatin. 4 weeks-6 weeks after neoadjuvant therapy, the patients accepted surgical treatment. One cycle of postoperative adjuvant treatment was given within 30 days after surgery, and 3 weeks after the completion of postoperative adjuvant treatment, Camrelizumab consolidation treatment was intiated, with a total of 13 cycles. The quality of life-C30 (QoL-C30) was used to measure patients' quality of life and the occurrence of AEs was monitored.
RESULTS:The overall safety is good, with a total of 300 AEs occurring in 66 patients, including 282 cases of grade 1-2 AEs and 18 cases of grades 3-4 AEs. The most common grades 3-4 AEs associated with PD-1 antibodies occurred in 6 cases (9.1%). Neoadjuvant therapy supervision can lead to a decrease in patients' QOL-C30 scores (P<0.05) and an improvement in their quality of life.
CONCLUSIONS:Camrelizumab combined with Docetaxel and Cisplatin can be used as a new adjuvant treatment for operable stage III NSCLC. Through the observation and control of AEs, treatment measures can be taken in time to reduce further complications, ensure patient' safety, and ensure the authenticity, scientificity and reliability of clinical trial data.
